Freeline gains on non-binding buyout offer from Syncona

seekingalpha2023-10-19

Freeline Therapeutics (NASDAQ:FRLN) added ~13% on Wednesday after its majority shareholder Syncona Portfolio Limited disclosed a non-binding proposal to acquire the clinical-stage biotech for $5 per ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2376441745?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1347295696/image_1347295696.jpg","is_english":true,"pubTime":"2023-10-19 00:10","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2376441745","market":"us","top_or_hot":-1,"title":"Freeline gains on non-binding buyout offer from Syncona","media":"seekingalpha","content":"<div>\n<p>Freeline Therapeutics (NASDAQ:FRLN) added ~13% on Wednesday after its majority shareholder Syncona Portfolio Limited disclosed a non-binding proposal to acquire the clinical-stage biotech for $5 per ...</p>\n\n<a href=\"https://seekingalpha.com/news/4021620-freeline-stock-gains-syncona-buyout-offer\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Freeline gains on non-binding buyout offer from Syncona</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFreeline gains on non-binding buyout offer from Syncona\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-10-19 00:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4021620-freeline-stock-gains-syncona-buyout-offer><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Freeline Therapeutics (NASDAQ:FRLN) added ~13% on Wednesday after its majority shareholder Syncona Portfolio Limited disclosed a non-binding proposal to acquire the clinical-stage biotech for $5 per ...</p>\n\n<a href=\"https://seekingalpha.com/news/4021620-freeline-stock-gains-syncona-buyout-offer\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://seekingalpha.com/news/4021620-freeline-stock-gains-syncona-buyout-offer","article_id":"2376441745","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1347295696/image_1347295696.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2376441745","pubTimestamp":1697645420,"columns":[],"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Freeline Therapeutics  added ~13% on Wednesday after its majority shareholder Syncona Portfolio Limited disclosed a non-binding proposal to acquire the clinical-stage biotech for $5 per ADS in an all-cash deal. The U.K.-based biotech said its board of directors has appointed a special panel of independent directors to evaluate Syncona’s bid and other strategic and financing opportunities. The company has engaged Leerink Partners LLC to deal with these initiatives.  Freeline Therapeutics  made its public debut in August 2020, raising $158.8M in gross proceeds. Shares of the gene therapy developer surged in March 2022 after Guernsey-based Syncona disclosed a ~63% stake in the company through a 13-D filing.  In April, the company increased the ratio between ADS and ordinary shares in a bid to regain compliance with the Nasdaq minimum bid price requirement.    More on Freeline Therapeutics  Freeline Therapeutics Holdings plc  Q2 2023 Earnings Call Transcript Freeline posts early data for g","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","FRLN":"Freeline Therapeutics Holdings plc"},"translate_title":"Syncona非约束性收购要约的Freeline收益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FRLN":1},"content_text":"Freeline Therapeutics (NASDAQ:FRLN) added ~13% on Wednesday after its majority shareholder Syncona Portfolio Limited disclosed a non-binding proposal to acquire the clinical-stage biotech for $5 per ADS in an all-cash deal. The U.K.-based biotech said its board of directors has appointed a special panel of independent directors to evaluate Syncona’s bid and other strategic and financing opportunities. The company has engaged Leerink Partners LLC to deal with these initiatives.  Freeline Therapeutics (FRLN) made its public debut in August 2020, raising $158.8M in gross proceeds. Shares of the gene therapy developer surged in March 2022 after Guernsey-based Syncona disclosed a ~63% stake in the company through a 13-D filing.  In April, the company increased the ratio between ADS and ordinary shares in a bid to regain compliance with the Nasdaq minimum bid price requirement.    More on Freeline Therapeutics  Freeline Therapeutics Holdings plc (FRLN) Q2 2023 Earnings Call Transcript Freeline posts early data for gene therapy in Gaucher disease Freeline Therapeutics GAAP EPS of -$0.23 beats by $3.28, revenue of $0.62M Seeking Alpha’s Quant Rating on Freeline Therapeutics Historical earnings data for Freeline Therapeutics","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2376441745"}